Company news
TuHURA Biosciences, Inc. news in 2026
TuHURA Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.
TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
November 13, 2026
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
November 4, 2026
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
October 26, 2026
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
October 13, 2026
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
October 5, 2026
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
September 14, 2026
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
August 14, 2026
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
July 22, 2026
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
June 15, 2026
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 15, 2026
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
May 12, 2026
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
April 21, 2026
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
April 6, 2026
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 31, 2026
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
March 23, 2026
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 27, 2026
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
February 23, 2026
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
February 17, 2026
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 12, 2026
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
February 2, 2026
Decks in 2026
- Investor Presentation (August 2026)
Investor deck · 24 slides · August 2026
- Investor Presentation (May 2026)
Investor deck · 23 slides · May 2026
- Investor Presentation (March 2026)
Investor deck · 23 slides · March 2026
- Investor Presentation (January 2026)
Investor deck · 29 slides · January 2026